Innate Pharma Logo

Innate Pharma

Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.

IPH | PA

Overview

Corporate Details

ISIN(s):
FR0010331421 (+1 more)
LEI:
9695002Y8420ZB8HJE29
Country:
France
Address:
117 AVENUE DE LUMINY, 13009 MARSEILLE

Description

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2018-06-04 07:00
CP en français
French 120.9 KB
2018-05-30 07:00
PR in English
English 69.4 KB
2018-05-30 07:00
CP en français
French 91.8 KB
2018-05-17 07:00
PR in English
English 106.2 KB
2018-05-17 07:00
CP en français
French 110.1 KB
2018-05-16 07:00
PR in English
English 86.6 KB
2018-05-16 07:00
CP en français
French 114.7 KB
2018-04-30 07:00
CP en français
French 80.2 KB
2018-04-30 07:00
PR in English
English 80.0 KB
2018-04-27 15:48
Document de référence 2017
French 2.8 MB
2018-04-17 20:00
CP en français
French 193.1 KB
2018-04-17 20:00
PR in English
English 194.9 KB
2018-04-17 07:00
CP en français
French 88.8 KB
2018-04-17 07:00
PR in English
English 86.1 KB
2018-04-09 07:00
CP en français
French 70.8 KB

Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Innate Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Innate Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-01-10 N/A Other Buy 6,000 N/A
2024-01-02 N/A Other Buy 20,000 N/A

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.